Christopher Peetz
CHIEF EXECUTIVE OFFICER at Mirum Pharmaceuticals; Director at Arcutis Biotherapeutics. Based in Foster City, California.
- Rank
- 2845th of 14,644
- Companies held
- 2
- Largest holding
- MIRM, 87.8% of total
- Latest SEC filing
- Nov 4, 2026
What the $42.8M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals MIRM Common Stock | Directly | 206,637 | $95.33 | $19.7M | 46.0% | Form 4, Nov 4, 2026 |
| Mirum Pharmaceuticals MIRM Common Stock | Through The Peetz Family Trust | 187,500 | $95.33 | $17.9M | 41.8% | Form 4, Nov 4, 2026 |
| Arcutis Biotherapeutics ARQT Common Stock | Through The Peetz Family Trust | 187,500 | $27.16 | $5.1M | 11.9% | Form 4, Jul 15, 2026 |
| Arcutis Biotherapeutics ARQT Common Stock | Directly | 4,315 | $27.16 | $117K | 0.3% | Form 4, Jul 15, 2026 |
Share counts are the amounts Christopher Peetz reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | Sold | MIRM | 20,000 | $90.00 | $1.8M | View |
| Sep 1, 2026 | Sold | MIRM | 8,312 | $98.08 | $815K | View |
| Sep 1, 2026 | Sold | MIRM | 21,688 | $98.91 | $2.1M | View |
| Aug 10, 2026 | Sold | MIRM | 6,017 | $99.25 | $597K | View |
| Aug 10, 2026 | Sold | MIRM | 11,683 | $98.51 | $1.2M | View |
| Aug 10, 2026 | Sold | MIRM | 2,300 | $100.14 | $230K | View |
| Jul 6, 2026 | Sold | MIRM | 12,134 | $121.65 | $1.5M | View |
| Jul 6, 2026 | Sold | MIRM | 4,181 | $122.34 | $512K | View |
| Jul 6, 2026 | Sold | MIRM | 1,710 | $124.79 | $213K | View |
| Jul 6, 2026 | Sold | MIRM | 1,975 | $123.74 | $244K | View |
| Jun 1, 2026 | Sold | MIRM | 883 | $99.66 | $88K | View |
| Jun 1, 2026 | Sold | MIRM | 1,021 | $98.20 | $100K | View |
| Jun 1, 2026 | Sold | MIRM | 1,973 | $97.56 | $192K | View |
| Jun 1, 2026 | Sold | MIRM | 6,926 | $96.15 | $666K | View |
| Jun 1, 2026 | Sold | MIRM | 16,595 | $95.34 | $1.6M | View |
| Jun 1, 2026 | Sold | MIRM | 2,602 | $94.64 | $246K | View |
| Mar 16, 2026 | Sold | MIRM | 40,985 | $91.98 | $3.8M | View |
| Feb 2, 2026 | Sold | MIRM | 9,108 | $103.30 | $941K | View |
| Jan 26, 2026 | Sold | MIRM | 6,831 | $96.19 | $657K | View |
| Jan 22, 2026 | Sold | MIRM | 7,098 | $93.33 | $662K | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 2842 | Scott J. Vassalluzzo Director, Cimpress. Boca Raton, FL | $42.9M |
| 2843 | Stuart J. Zimmer Director, Ategrity Specialty Insurance Company. New York, NY | $42.9M |
| 2844 | Chris M. Calcaterra Chief Operating Officer, Glaukos. San Clemente, CA | $42.8M |
| 2845 | Christopher Peetz CHIEF EXECUTIVE OFFICER, Mirum Pharmaceuticals. Foster City, CA | $42.8M |
| 2846 | Gautam Patel Director, Amneal Pharmaceuticals. Bridgewater, NJ | $42.8M |
| 2847 | M. Troy Woods Director, Global Payments. Atlanta, GA | $42.7M |
| 2848 | Robert W. Johnson Director, Viasat. Carlsbad, CA | $42.7M |
Other Mirum Pharmaceuticals insiders
All MIRM insiders- Michael G. Grey$26.7MDirector. #4114 overall
- Lara Longpre$10.0MCHIEF DEVELOPMENT OFFICER. #8829 overall
- Pamela Vig$9.8MCHIEF SCIENTIFIC OFFICER. #8961 overall
- Peter Radovich$5.5MPRESIDENT AND COO. #13637 overall
- Scott D. Sandell$1.2M10% owner. #1780 overall
Questions
How much stock does Christopher Peetz own?
Christopher Peetz holds $42,781,817 in listed stock based on SEC filings and current prices, mostly Mirum Pharmaceuticals (MIRM). That ranks 2845th on the Stock Rich List.
Is this Christopher Peetz's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Christopher Peetz last buy or sell stock?
The most recent open-market trade on file is a sale of 20,000 MIRM shares on Nov 4, 2026 at $90.00.